 Patient Name		Patient Name	Patient Name
 DOB	_	DOB	DOB
502750	UA	502750	502750



Revision 7



 Customer I	nformation	

8430 Juniper Creek Lane, Sar Tel: (858) 217-5918 Fax: (866 Lab Director: Nicholas Bevin CLIA #05D0567262	5) 789-9585 s, M.D., Ph.D.	Birdrock				
		CULAR DIAGNOSTIC				
Last Name:			///			
First Name:	B	Biological Sex: 🗌 M 🔲	F Ordering Provider:			
Date Collected:			ent demographics with			
Time Collected:	: AM / PM	Uninsured P	,	insurance card		
Ethnicity: (for Covid Testing)	Only) Diagno	osis Code(s)*				
•	•	tino/Spanish Origin	□ □ American Indian/Alask	an Native		
		Refu		arrivative		
				rable Local Coverage Determinations (LCDs)		
		NELS, EACH PANEL WILL REQU				
	RY TRACT INFECTION			RY PATHOGEN TESTS		
ORINA	BD Vacutainer C&S Tube (gray)	12313	Respiratory and Vi	ral Transport Medium (red top)		
Urinalysis UA Preservative 7	Tube Required		Respiratory Pathogen Menu			
Complete UTI Panel with An	tibiotic Resistance Menu	w/ Sensitivity	Influenza A (incl. H1, H3, H5, and H7)			
Urinary Tract Infection Men			Flu Typing (Influenza A serotypes pdH1N1, H3, and H3N2)			
Acinetobacter baumannii	Sulfonamide resistar		☐ Influenza B (Yamagata and Victoria lineages) ☐ Respiratory Syncytial Virus (incl. type A and B)			
Candida albicans			SARS-CoV2-2 a (ORF1 gene)			
Citrobacter freundii						
Candida glabrata						
Enterobacter cloacae		B-lactamase pan-TEM	SEXUALLY TRANS	MITTED INFECTION TESTS		
Enterococcus faecalis		PD Vacutainay COS Tuba (avay)				
Escherichia coli	☐ Klebsiella pneumoni	iae carbapenase resistance kpc	Complete STI Panel w	rith Resistance Markers & Pathogenic Flora		
Methicillin-resistance Staph aureu				<u>_</u>		
Klebsiella pneumoniae	Glycopeptide resista		Major STI	Conditionally Pathogenic Flora		
Morganella morganii	Glycopeptide resista		Chlamydia trachomatis Chlamydia trachomatis LGV	Ureaplasma urealyticum Ureaplasma parvum		
Proteus mirabilis	Macrolide resistance		Neisseria gonorrhoeae	Mycoplasma hominis		
Pseudomonas aeruginosa  Staphylococcus aureus	Macrolide resistance		Trichomonas vaginalis	Resistance Markers		
Staphylococcus saprophyticus		equinolone resistance QnrA and QnrS	Mycoplasma genitalium	M.genitalium macrolide resistance		
Streptococcus agalactiae		oquinolone resistance QnrB Clade 1-2		M.genitalium fluoroquinolone resistance		
	TERIAL VAGINOSIS PA			N.gonorrhoeae ceftriaxon resistance		
	E-Swabs	Continuo de la constitución	■ SARS-CoV-21	Respiratory via RT-qPCR		
Complete Panel	Lactobacillus gasseri Candida albicans	Candida parapsilosis Gardnerella vaginalis	Red or Purple Viral Transport Medium			
Lactobacillus iners	Candida tropicalis	Atopobium vaginae				
Lactobacillus crispatus	Candida glabrata	Trichomonas vaginalis	Group B Streptococcus			
Lactobacillus jensenii	Candida krusei		Nas	sopharyngeal Swab		
AUTHORIZATION/SIGN	IATUDES					
DONOR: I certify that the specimen and/or alcohol. I authorize Birdrock Lab denial, and authorize all reimbursemen I may be responsible for the amount du	and information provided is my own a oratories to share the information on t ts to be paid directly to the laboratory e as determined by said insurance. I au	this form and my test results with my desig r in consideration of services performed. I a uthorize Birdrock Laboratories to release th	nated insurance carrier if necessary for cknowledge that Birdrock Laboratories he results of this testing to the treating	ting of my specimen for the presence of drugs r reimbursement, to appeal any reimbursement s may be outside my network of insurance and authorized healthcare provider or facility. n individual patient. Section 1862(a)(1)(A) of the		

Social Security Act states, "no payment may be made under Part A or Part B for any expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member." Tests submitted for Medicare reimbursement must meet program requirements or the claim may be denied. I certify that the above ordered tests are medically necessary for the diagnosis and treatment of this patient. I have documented this test in the patient's chart. I acknowledge that Medicare does not generally cover routine screening tests.

Donor Authorization Signature: Date: Ordering Health Care Provider Signature (Required): Date (Required):